• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

EZM 2302

CAS No. 1628830-21-6

EZM 2302 ( GSK 3359088 | GSK3359088 | EZM2302 )

产品货号. M12435 CAS No. 1628830-21-6

EZM 2302 (EZM2302, GSK 3359088) 是一种有效的、选择性的、口服的精氨酸甲基转移酶 CARM1 抑制剂,IC50 为 6 nM。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥1345 有现货
10MG ¥2001 有现货
25MG ¥3839 有现货
50MG ¥5095 有现货
100MG ¥7250 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    EZM 2302
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    EZM 2302 (EZM2302, GSK 3359088) 是一种有效的、选择性的、口服的精氨酸甲基转移酶 CARM1 抑制剂,IC50 为 6 nM。
  • 产品描述
    EZM 2302 (EZM2302, GSK 3359088)?is a potent, selective, orally available arginine methyltransferase CARM1 inhibitor with IC50 of 6 nM, with broad selectivity against other HMTases; demonstrates in vitro anti-proliferative activity consistent with specific methyl mark inhibition with IC50 of <100 nM in 9/15 multiple myeloma cell lines, decreases methylation of PABP1 (IC50?=38 nM) and SmB (IC50=18 nM); displays dose-dependent inhibition of CARM1 substrate methylation in vivo, and induces growth inhibition of human multiple myeloma tumor xenografts in mice.
  • 体外实验
    EZM 2302 binds to CARM1 and is a selective inhibitor of CARM1 activity (IC50=6?nM) with broad selectivity against other histone methyltransferases. Treatment of MM cell lines with EZM 2302 leads to inhibition of PABP1 and SMB methylation and cell stasis with IC50 values in the nanomolar range (9, 31 nM, respectively). EZM 2302 inhibits the in vitro proliferation of multiple hematopoietic cell lines, with day 14 IC50 values of less than 100?nM in 9 of 15 cell lines.
  • 体内实验
    EZM 2302 is stable in human hepatocytes (CL<3?mL/min/kg), and moderately binds to human, mouse and rat plasma proteins with a mean fraction unbound of 0.66, 0.46 and 0.74, respectively. In mouse and rat, the plasma clearance (CL) is 43 and 91?mL/min/kg, respectively. EZM 2302 shows dose-dependent exposure and tumor growth inhibition (TGI) after 21 days in the RPMI-8226 xenograft model. Tumors in all EZM 2302 dose groups measured on day 21 show significant decreases in tumor growth compared to vehicle.
  • 同义词
    GSK 3359088 | GSK3359088 | EZM2302
  • 通路
    Chromatin/Epigenetic
  • 靶点
    HMTase
  • 受体
    HMTase
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    1628830-21-6
  • 分子量
    585.102
  • 分子式
    C29H37ClN6O5
  • 纯度
    >98% (HPLC)
  • 溶解度
    100 mM in DMSO
  • SMILES
    O=C(N(CC1)CCC21CN(C3=NC(C4=CC(OC[C@H](O)CNC)=CC=C4Cl)=NC(C5=C(C)ON=C5C)=C3C)C2)OC
  • 化学全称
    methyl (R)-2-(2-(2-chloro-5-(2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Drew AE, et al. Sci Rep. 2017 Dec 21;7(1):17993. 2. Greenblatt SM, et al. Cancer Cell. 2018 Jun 11;33(6):1111-1127.e5.
产品手册
关联产品
  • UNC3866

    一种有效的选择性 PRC1 染色质结构域拮抗剂,可与 CBX4 和 CBX7 结合,Kd 为 100 nM。

  • MI-2 (Menin-MLL Inhi...

    MI-2 (Menin-MLL Inhibitor) 是一种有效的 menin-MLL 相互作用抑制剂,IC50 为 446 nM。

  • SGC-2085

    SGC-2085 是一种有效的选择性蛋白精氨酸甲基转移酶 PRMT4 (CARM1) 抑制剂,IC50 为 50 nM。